MediWound (NASDAQ:MDWD) Stock Passes Below 200-Day Moving Average – What’s Next?

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $17.72 and traded as low as $17.61. MediWound shares last traded at $17.73, with a volume of 23,348 shares trading hands.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of MediWound in a report on Friday, January 10th.

MediWound Trading Down 4.8 %

The company has a fifty day simple moving average of $18.21 and a two-hundred day simple moving average of $17.74. The company has a market cap of $191.18 million, a PE ratio of -6.11 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last issued its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter last year, the company posted ($0.24) EPS. On average, research analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Trading of MediWound

Several institutional investors and hedge funds have recently bought and sold shares of MDWD. Investor AB purchased a new stake in shares of MediWound in the third quarter valued at about $15,750,000. Yelin Lapidot Holdings Management Ltd. raised its stake in MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock valued at $15,154,000 after acquiring an additional 100,618 shares during the last quarter. Rosalind Advisors Inc. lifted its position in MediWound by 22.3% during the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after acquiring an additional 114,560 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after purchasing an additional 35,012 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.